Nykredit A S Purchases New Shares in Zoetis Inc. $ZTS

Nykredit A S acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 139,745 shares of the company’s stock, valued at approximately $10,042,000.

A number of other large investors have also made changes to their positions in the company. RFG Advisory LLC boosted its holdings in shares of Zoetis by 4.9% during the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares during the period. Financial Engines Advisors L.L.C. lifted its position in Zoetis by 4.4% in the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after buying an additional 87 shares in the last quarter. Physician Wealth Advisors Inc. boosted its stake in shares of Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after buying an additional 91 shares during the period. Smithfield Trust Co grew its holdings in shares of Zoetis by 4.2% during the 4th quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after acquiring an additional 92 shares in the last quarter. Finally, Howland Capital Management LLC grew its holdings in shares of Zoetis by 4.5% during the 2nd quarter. Howland Capital Management LLC now owns 2,137 shares of the company’s stock valued at $333,000 after acquiring an additional 92 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.8%

Shares of ZTS stock opened at $75.70 on Friday. The stock’s 50 day simple moving average is $75.53 and its 200 day simple moving average is $93.85. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $155.15. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company has a market capitalization of $31.28 billion, a price-to-earnings ratio of 12.47, a PEG ratio of 1.77 and a beta of 0.73.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the prior year, the business earned $1.76 earnings per share. The company’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.2 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Weiss Ratings lowered Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. JPMorgan Chase & Co. dropped their target price on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. HSBC reduced their price target on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. Finally, William Blair reissued a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $107.43.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.